Enzalutamide inhibits androgen receptor-positive bladder cancer cell growth.

[1]  D. Rathkopf,et al.  Novel and next-generation androgen receptor-directed therapies for prostate cancer: Beyond abiraterone and enzalutamide. , 2016, Urologic oncology.

[2]  S. Bunimovich-Mendrazitsky,et al.  Key signaling pathways in the muscle‐invasive bladder carcinoma: Clinical markers for disease modeling and optimized treatment , 2016, International journal of cancer.

[3]  H. Ide,et al.  Steroid Hormone Receptor Signals as Prognosticators for Urothelial Tumor , 2015, Disease markers.

[4]  S. Inoue,et al.  Compound A Inhibits Bladder Cancer Growth Predominantly via Glucocorticoid Receptor Transrepression. , 2015, Molecular endocrinology.

[5]  G. Netto,et al.  ELK1 is up-regulated by androgen in bladder cancer cells and promotes tumor progression , 2015, Oncotarget.

[6]  H. Scher,et al.  Enzalutamide: Development from bench to bedside. , 2015, Urologic oncology.

[7]  H. Honda,et al.  Secondary bladder cancer after anticancer therapy for prostate cancer: reduced comorbidity after androgen-deprivation therapy , 2015, Oncotarget.

[8]  P. Olbert,et al.  TLR4- and TLR9-dependent effects on cytokines, cell viability, and invasion in human bladder cancer cells. , 2015, Urologic oncology.

[9]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[10]  Hong-Chiang Chang,et al.  Fibroblast ERα promotes bladder cancer invasion via increasing the CCL1 and IL-6 signals in the tumor microenvironment. , 2015, American journal of cancer research.

[11]  G. Netto,et al.  Cyclosporine A and tacrolimus inhibit bladder cancer growth through down-regulation of NFATc1 , 2015, Oncotarget.

[12]  Kotaro Suzuki,et al.  Androgen deprivation therapy prevents bladder cancer recurrence , 2014, Oncotarget.

[13]  A. Masson-Lecomte,et al.  Gender-specific differences in clinicopathologic outcomes following radical cystectomy: an international multi-institutional study of more than 8000 patients. , 2014, European urology.

[14]  Yi Li,et al.  GATA3 in the urinary bladder: suppression of neoplastic transformation and down-regulation by androgens. , 2014, American journal of cancer research.

[15]  E. Messing,et al.  Estrogen receptor alpha prevents bladder cancer via INPP4B inhibited akt pathway in vitro and in vivo. , 2014 .

[16]  Yifeng Jing,et al.  Activated androgen receptor promotes bladder cancer metastasis via Slug mediated epithelial-mesenchymal transition. , 2014, Cancer letters.

[17]  Z. Culig.  Targeting the androgen receptor in prostate cancer , 2014, Expert opinion on pharmacotherapy.

[18]  T. Miyamoto.  Androgen Receptor Antagonists in the Treatment of Prostate Cancer , 2014 .

[19]  G. Netto,et al.  Expression of UDP‐glucuronosyltransferase 1A in bladder cancer: Association with prognosis and regulation by estrogen , 2014, Molecular carcinogenesis.

[20]  Chawnshang Chang,et al.  Epidermal growth factor enhances androgen receptor‑mediated bladder cancer progression and invasion via potentiation of AR transactivation. , 2013, Oncology reports.

[21]  P. Humphrey,et al.  Constitutive β-catenin activation induces male-specific tumorigenesis in the bladder urothelium. , 2013, Cancer research.

[22]  Yi Li,et al.  Androgen activates β-catenin signaling in bladder cancer cells. , 2013, Endocrine-related cancer.

[23]  A. Zietman,et al.  Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base. , 2013, European urology.

[24]  Xue-Ru Wu,et al.  Decreased tumorigenesis and mortality from bladder cancer in mice lacking urothelial androgen receptor. , 2013, The American journal of pathology.

[25]  Chawnshang Chang,et al.  Androgen receptor signals regulate UDP‐glucuronosyltransferases in the urinary bladder: A potential mechanism of androgen‐induced bladder carcinogenesis , 2013, Molecular carcinogenesis.

[26]  H. Frierson,et al.  CD24 expression is important in male urothelial tumorigenesis and metastasis in mice and is androgen regulated , 2012, Proceedings of the National Academy of Sciences.

[27]  Yi Li,et al.  Epidermal growth factor induces bladder cancer cell proliferation through activation of the androgen receptor , 2012, International journal of oncology.

[28]  K. Kuroiwa,et al.  Androgen receptor signaling regulates cell growth and vulnerability to doxorubicin in bladder cancer. , 2012, The Journal of urology.

[29]  Jorge Yao,et al.  Dihydrotestosterone upregulates the expression of epidermal growth factor receptor and ERBB2 in androgen receptor-positive bladder cancer cells. , 2011, Endocrine-related cancer.

[30]  D. Tindall,et al.  Minireview: Alternative activation pathways for the androgen receptor in prostate cancer. , 2011, Molecular endocrinology.

[31]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[32]  C. Chuang,et al.  Profiling of matrix metalloproteinases and tissue inhibitors of metalloproteinases proteins in bladder urothelial carcinoma. , 2010, Oncology letters.

[33]  S. Xia,et al.  Androgen receptor is a potential therapeutic target for bladder cancer. , 2010, Urology.

[34]  H. Scher,et al.  Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer , 2009, Science.

[35]  Aimee M. Johnson,et al.  Androgenic dependence of exophytic tumor growth in a transgenic mouse model of bladder cancer: a role for thrombospondin-1 , 2008, BMC urology.

[36]  D. Jarrard,et al.  Roles of estrogen receptor alpha and beta in modulating urothelial cell proliferation. , 2008, Endocrine-related cancer.

[37]  E. Messing,et al.  Promotion of bladder cancer development and progression by androgen receptor signals. , 2007, Journal of the National Cancer Institute.

[38]  C. Heinlein,et al.  Androgen receptor in prostate cancer. , 2004, Endocrine reviews.

[39]  W. M. Linehan,et al.  Unexplained excess risk of bladder cancer in men. , 1990, Journal of the National Cancer Institute.